Bringing life into balance
Dedicated to rapidly and directly disrupting the central mechanism of Graves’ disease and TED
Patients with Graves’ disease and TED need a better option
Current treatments are limited and associated with serious side effects that may restrict benefits or have long term health impacts.
Disrupting the disease process at the source
YB-101 is designed to rapidly and directly disrupt the central mechanism of Graves’ disease and TED by blocking the interaction of autoantibodies with the TSH receptor.